
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer demonstrated strong financial performance in 4Q 2024, surpassing both internal and consensus estimates due to increased sales of key products such as Comirnaty, Paxlovid, Eliquis, and Ibrance, despite lower-than-expected revenues from Abrysvo. The company’s management has maintained its FY 2025 guidance, focusing on stabilizing COVID-19 revenues while pursuing cost realignment and leveraging pipeline opportunities to enhance future growth. Additionally, there is optimism regarding clinical updates from Pfizer's obesity and oncology pipelines, expected in 2025, which may further solidify the company's market position and drive stock performance.
Bears say
Pfizer's outlook is negatively affected by several factors, including disappointing commercial performance of key products such as Padcev and Abrysvo, alongside potential regulatory setbacks for pipeline drugs. The company has made model adjustments that reflect a decrease in near-term sales projections for specific drugs while attempting to realign costs, indicating challenges in growth stability. Additionally, ongoing concerns over US drug pricing reforms may dampen investor interest in Pfizer amidst its reliance on higher-priced medicines, suggesting a potentially diminishing market appeal.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares